Your browser doesn't support javascript.
loading
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
Gorman, Matthew J; Patel, Nita; Guebre-Xabier, Mimi; Zhu, Alex L; Atyeo, Caroline; Pullen, Krista M; Loos, Carolin; Goez-Gazi, Yenny; Carrion, Ricardo; Tian, Jing-Hui; Yuan, Dansu; Bowman, Kathryn A; Zhou, Bin; Maciejewski, Sonia; McGrath, Marisa E; Logue, James; Frieman, Matthew B; Montefiori, David; Mann, Colin; Schendel, Sharon; Amanat, Fatima; Krammer, Florian; Saphire, Erica Ollmann; Lauffenburger, Douglas A; Greene, Ann M; Portnoff, Alyse D; Massare, Michael J; Ellingsworth, Larry; Glenn, Gregory; Smith, Gale; Alter, Galit.
Afiliación
  • Gorman MJ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Patel N; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
  • Guebre-Xabier M; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
  • Zhu AL; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Atyeo C; Virology and Immunology Program, University of Duisburg-Essen, Essen, Germany.
  • Pullen KM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Loos C; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Goez-Gazi Y; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Carrion R; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Tian JH; Texas Biomedical Research Institute, 8715 West Military Drive, San Antonio, TX 78227, USA.
  • Yuan D; Texas Biomedical Research Institute, 8715 West Military Drive, San Antonio, TX 78227, USA.
  • Bowman KA; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
  • Zhou B; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • Maciejewski S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
  • McGrath ME; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
  • Logue J; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
  • Frieman MB; University of Maryland School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA.
  • Montefiori D; University of Maryland School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA.
  • Mann C; University of Maryland School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA.
  • Schendel S; Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
  • Amanat F; La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Krammer F; La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Saphire EO; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lauffenburger DA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Greene AM; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Portnoff AD; La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Massare MJ; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Ellingsworth L; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
  • Glenn G; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
  • Smith G; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
  • Alter G; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA.
Cell Rep Med ; 2(9): 100405, 2021 09 21.
Article en En | MEDLINE | ID: mdl-34485950
ABSTRACT
Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thus, we profiled the humoral immune response in a cohort of non-human primates immunized with a recombinant SARS-CoV-2 spike glycoprotein (NVX-CoV2373) at two doses, administered as a single- or two-dose regimen. Both antigen dose and boosting significantly altered neutralization titers and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were associated with distinct levels of protection in the upper and lower respiratory tract. Moreover, NVX-CoV2373 elicited antibodies that functionally targeted emerging SARS-CoV-2 variants. Collectively, the data presented here suggest that a single dose may prevent disease via combined Fc/Fab functions but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Saponinas / Vacunas contra la COVID-19 / SARS-CoV-2 Límite: Animals Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Saponinas / Vacunas contra la COVID-19 / SARS-CoV-2 Límite: Animals Idioma: En Año: 2021 Tipo del documento: Article